Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 425-432

  Zhu, Chan ^a,b   Pan, Yuqin ^b   He, Bangshun ^b   Wang, Bo ^a,b   Xu, Yongfei ^a,b   Qu, Lili ^b   Bao, Qian ^a,b   Tian, Fuliang ^a,b   Wang, Shukui ^a,b  

^a NANJING NORMAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

CD147; Chemosensitivity; Laryngeal carcinoma; RNA interference

Indexed keywords

CD147 ANTIGEN; CISPLATIN; GELATINASE A; GELATINASE B; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENICITY; CARCINOMA CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LARYNX CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR CELL;

ANIMALS; ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LARYNGEAL NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651360297     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1088     Document Type: Article

References (38)

1. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidency of eighteen major cancers in 1985. Int J Cancer 54: 594-606, 1993.
2. Ferlay J, Bray F, Pisani P and Parkin DM: Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancer Base No. 5. IARC Press, Lyon, 2001.
3. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
4. Ampil FL, Nathan CO, Caldito G, Lian TF, Aarstad RF and Krishnamsetty RM: Total laryngectomy and postoperative radiotherapy for T4 laryngeal cancer: a 14-year review. Am J Otolaryngol 25: 88-93, 2004. (Pubitemid 38418967)
5. Yu H, Xin YF, Duan XD, Zhu LX and Jin DJ: Dynamic analysis of epidemiology and etiology on laryngeal carcinoma. Mod Biomed Progr 3: 393-395, 2007.
6. Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R and Gladson CL: Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113: 1406-1410, 2003. (Pubitemid 36944687)
7. Hanata K, Yamaguchi N, Yoshikawa K, et al: Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch Histol Cytol 70: 267-277, 2007. (Pubitemid 351594918)
8. Shinsuke S, Mitsuru S, Haruki S and Kazuo I: Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 293: 259-266, 2004.
9. Sameshima T, Nabeshima K, Toole BP, et al: Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88: 21-27, 2000.
10. Kanekura T, Chen X and Kanzaki T: Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99: 520-528, 2002. (Pubitemid 34461604)
11. Jiang JL, Zhou Q, Yu MK, Ho LS, Chen ZN and Chan HC: The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 276: 46870-46877, 2001. (Pubitemid 37373056)
12. Zucker S, Hymowitz M, Rollo EE, et al: Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 158: 1921-1928, 2001.
13. Reimers N, Zafrakas K, Assmann V, et al: Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 10: 3422-3428, 2004. (Pubitemid 38685448)
14. Iacono KT, Brown AL, Greene MI and Saouaf SJ: CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 83: 283-295, 2007.
15. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
16. Zou W, Yang H, Hou X, Zhang W, Chen B and Xin X: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 248: 211-218, 2007. (Pubitemid 46330554)
17. Tang Y: Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 4: 371-377, 2006. (Pubitemid 44035156)
18. Yurchenko V, O'Connor M, Dai WW, Guo H, Toole B, Sherry B and Bukrinsky M: CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 288: 786-788, 2001.
19. Tang W, Chang S and BandHemler ME: Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 15: 4043-4050, 2004. (Pubitemid 39122010)
20. Chen X, Lin J, Kanekura T, et al: A small interfering CD147- targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res 66: 11323-11330, 2006. (Pubitemid 46009963)
21. Tang Y, Nakada MT, Kesavan P, et al: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199, 2005. (Pubitemid 40524601)
22. Marieb EA, Zoltan-Jones A, Li R, et al: Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 64: 1229-1232, 2004. (Pubitemid 38235586)
23. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN and Halestrap AP: CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 19: 3896-3904, 2000. (Pubitemid 30608530)
24. Misra S: Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 278: 25285-25288, 2003. (Pubitemid 36835275)
25. Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528-539, 2004.
26. Qian AR, Wei Z, Cao JP, et al: Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. J Exp Clin Cancer Res 27: 50, 2008.
27. Min L, Qihui Z, Uddalak B, et al: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 106: 2284-2294, 2006. (Pubitemid 43673252)
28. Xu D and Hemler ME: Metabolic activation-related CD147- CD98 complex. Mol Cell Proteomics 4: 1061-1071, 2005. (Pubitemid 41223366)
29. Su J, Chen X and Kanekura T: A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273: 140-147, 2009.
30. Li HG, Xie DR, Shen XM, Li HH, Zeng H and Zeng YJ: Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 11: 1445-1451, 2005. (Pubitemid 40468078)
31. MacDougall JR, Bani MR, Lin Y, Rak J and Kerbel RS: The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res 55: 4174-4181, 1995.
32. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185: 256-261, 1998. (Pubitemid 28320046)
33. Cheng MF, Tzao C, Tsai WC, et al: Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus 19: 482-486, 2006. (Pubitemid 44644686)
34. Lee J, Yongsong S, Choi J, et al: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Human Pathol 36: 626-633, 2005. (Pubitemid 40922568)
35. Han ZD, He HC, Bi XC, et al: Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 160: 260-267, 2010.
36. Jia L, Wang H, Qu S, Miao X and Zhang J: CD147 regulates vascular endothelial growth factor-A expression, tumorigenicity, and chemosensitivity to curcumin in hepatocellular carcinoma. IUBMB Life 60: 57-63, 2008.
37. Higham P, Quek S and Cohen HV: Dental management for head and neck cancer patients undergoing radiation therapy: comprehensive patient based planning, a case report. JNJ Dent Assoc 80: 31-33, 2009.
38. Fuertes MA, Castilla J and Alonso CandPerez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10: 257-266, 2003. (Pubitemid 36131658)